logo-loader
viewLexagene Holdings Inc.

LexaGene Holdings boosts senior team to help prepare for LX Analyzer launch in 2020

Steven Armstrong will play a key role in helping the firm prepare its submission to the FDA Emergency Use Authorization of its commercial technology

Lexagene Holdings Inc. -
The firm is accelerating the submission of its LX Analyzer to the US Food and Drug Administration as the coronavirus outbreak expands

LexaGene Holdings Inc (CVE:LXG) (OTCMKTS:LXXGF) said it is adding additional strength to its team as it continues to work towards commercializing its genetic analyzer for pathogen detection.

The Beverly, Massachusetts-based company is bringing on medical device expert Steven Armstrong as senior director of operations, it announced Tuesday.

Armstrong will play a key role in helping the firm prepare its submission to a US Food & Drug Administration (FDA) Emergency Use Authorization of its commercial technology and other regulatory approvals. 

READ: LexaGene accelerates submission of its LX Analyzer to the FDA as coronavirus outbreak expands

“I’m thrilled that Mr Armstrong has joined the team to guide us during this next phase of commercial manufacturing,” LexaGene CEO Jack Regan said in a statement.

“We are taking every measure to hasten our readiness for FDA approval, not only for our commercial analyzer, but also for the test chemistry of our diagnostic panels. Mr. Armstrong has an enormous amount of experience in navigating the regulatory clearance landscape, as well as launching innovative medical devices, and I look forward to the leadership he will provide LexaGene in getting to the commercial finish line faster.”

Throughout his career, Armstrong has overseen the global operations of complex medical devices and obtained FDA and regulatory approvals for over 50 devices in 10 countries. He was directly involved in the development and launch of LASIK technology and has vast experience with laser and light-based technologies.

Combating coronavirus

LexaGene has revealed that it will soon start manufacturing its flagship LX Genetic Analyzer for rapid pathogen detection, with an anticipated commercial launch in 2020.

The firm recently revealed that it is accelerating the submission of its LX Analyzer to the FDA as the coronavirus (COVID-19) outbreak expands.

In response so far, the FDA has encouraged labs and manufacturers to submit applications for Emergency Use Authorization to help address the lack of quality diagnostics to fight this disease.  

“The current COVID-19 diagnostic crisis has prevented effective mitigation and treatment measures to date,” CEO Regan told shareholders.

“At LexaGene, we have rapidly turned our attention to this problem and have dedicated resources towards setting up a quality system that is required for FDA diagnostic devices and pushing forward manufacturing as quickly as possible. Laying this groundwork is necessary so that we can contribute to solving this crisis by providing a solution for rapid point-of-need diagnostics that can easily be configured for new tests as needed.”

Contact Angela at [email protected]

Follow her on Twitter @AHarmantas

Quick facts: Lexagene Holdings Inc.

Price: 0.98 CAD

TSX-V:LXG
Market: TSX-V
Market Cap: $87.74 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Lexagene Holdings Inc. named herein, including the promotion by the Company of Lexagene Holdings Inc. in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: LexaGene hits milestone by having pre-commercial device in...

LexaGene (CVE: LXG- OTCQB: LXXGF) CEO Dr Jack Regan joined Steve Darling from Proactive Vancouver with news the company now has one of their devices that tests for COVID-19 and other respiratory pathogens being used at the Dartmouth-Hitchcock Medical Center in Hanover, New Hampshire. Regan...

on 28/5/20

3 min read